公开(公告)号：WO2023023583A1

公开(公告)日：2023-02-23

申请号：PCT/US2022/075121

申请日：2022-08-18

Applicant: NUWELLIS, INC. ,  LERNER, David ,  HASKVITZ, David, J. ,  BERG, Kalley, Francis ,  SANDOVAL, Steven, Daniel

Inventor： LERNER, David ,  HASKVITZ, David, J. ,  BERG, Kalley, Francis ,  SANDOVAL, Steven, Daniel

IPC: A61M1/34 ,  A61M1/36

Abstract: A blood filtration system can be used with an external infusion pump and can include, among other things, a withdrawal line, an infusion (return) line, a filter coupled between the withdrawal line and the infusion line, a controller, and a withdrawal pressure sensor and/or an infusion pressure sensor. The withdrawal pressure sensor can sense a withdrawal pressure signal indicative of a pressure in the withdrawal line. The infusion pressure sensor can be coupled to the infusion line to sense an infusion pressure signal indicative of a pressure in the infusion line. In various embodiments, the controller can detect an operational state of the external infusion pump by analyzing at least the withdrawal pressure signal and/or the infusion pressure signal.

公开(公告)号：WO2022147476A1

公开(公告)日：2022-07-07

申请号：PCT/US2021/073199

申请日：2021-12-30

Applicant: NUWELLIS, INC. ,  LERNER, David

Inventor： LERNER, David

IPC: A61M1/14 ,  A61M1/16 ,  A61M1/34 ,  A61M5/165

Abstract: A catheter may include a withdrawal lumen wall extending around a withdrawal lumen. The withdrawal lumen may have a withdrawal lumen profile. The catheter may include an infusion lumen wall coupled with the withdrawal lumen wall. The infusion lumen wall may extend around an infusion lumen. The infusion lumen may have an infusion lumen profile smaller than the withdrawal lumen profile. A flexible septum may extend between the withdrawal lumen and the infusion lumen. The flexible septum may isolate the withdrawal lumen from the infusion lumen. In another example, a blood filtration system may monitor blood flow velocity within vasculature. The blood filtration system may guide operation of a blood pump or a filtrate bump based on the blood flow velocity within the vasculature.

公开(公告)号：WO2017040218A1

公开(公告)日：2017-03-09

申请号：PCT/US2016/048766

申请日：2016-08-25

Applicant: SUNSHINE HEART COMPANY PTY LTD. ,  OLSON, David ,  KNUTTILA, Aaron ,  TAS, Tolga ,  LERNER, David

Inventor： OLSON, David ,  KNUTTILA, Aaron ,  TAS, Tolga ,  LERNER, David

IPC: A61N1/36 ,  A61B5/0205 ,  A61N1/05 ,  A61N1/362 ,  A61N1/372 ,  A61M1/10 ,  A61M1/12

CPC classification number: A61N1/36114 ,  A61B5/0205 ,  A61M1/1055 ,  A61M1/1067 ,  A61M1/122 ,  A61N1/0556 ,  A61N1/36117 ,  A61N1/36139 ,  A61N1/3627 ,  A61N1/37288

Abstract: An example electrical stimulation system for use in combination with a non-pulsatile or low-pulsatile ventricular assist device and for restoration of autonomic balance by stimulating at least one nerve. The system includes a stimulation source including a controller configured to control delivery of electrical stimulation at a stimulation rate modeled to simulate a baroreceptor discharge related to an intrinsic heart rate, a lead operably coupled to the stimulation source, and at least one electrode operably coupled to the lead, wherein the at least one electrode is positionable in contact with or adjacent to the at least one nerve.

Abstract translation: 用于与非脉动或低搏动心室辅助装置组合使用的示例性电刺激系统，以及通过刺激至少一个神经来恢复自主平衡。 所述系统包括刺激源，所述刺激源包括控制器，所述控制器被配置成以刺激速率控制电刺激的传递，所述刺激速率被建模为模拟与内在心率相关的压力感受器放电，可操作地耦合到所述刺激源的引线，以及至少一个电极， 所述引线，其中所述至少一个电极可定位成与所述至少一个神经接触或相邻。

公开(公告)号：WO2003039602A3

公开(公告)日：2003-05-15

申请号：PCT/US2002/030998

申请日：2002-09-30

Applicant: QUICK MED TECHNOLOGIES, INC. ,  UNIVERSITY OF FLORIDA ,  BATICH, Christopher, D. ,  SCHULTZ, Gregory ,  MAST, Bruce, A. ,  OLDERMAN, Gerald, M. ,  LERNER, David, S. ,  TOREKI, William ,  GRANITO, Michael, R.

Inventor： BATICH, Christopher, D. ,  SCHULTZ, Gregory ,  MAST, Bruce, A. ,  OLDERMAN, Gerald, M. ,  LERNER, David, S. ,  TOREKI, William ,  GRANITO, Michael, R.

IPC: B05D3/00

Abstract: This invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings, powders and other substrates. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymer chains and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial efficacy.

公开(公告)号：WO0033778A9

公开(公告)日：2001-11-15

申请号：PCT/US9929091

申请日：1999-12-08

Applicant: QUICK MED TECHNOLOGIES INC ,  UNIV FLORIDA ,  BATICH CHRISTOPHER D ,  SCHULTZ GREGORY S ,  MAST BRUCE A ,  OLDERMAN GERALD M ,  LERNER DAVID

Inventor： BATICH CHRISTOPHER D ,  SCHULTZ GREGORY S ,  MAST BRUCE A ,  OLDERMAN GERALD M ,  LERNER DAVID

IPC: A61F13/49 ,  A61F5/441 ,  A61F13/00 ,  A61F13/15 ,  A61F13/20 ,  A61F13/472 ,  A61F13/53 ,  A61L2/16

CPC classification number: A61F13/8405

Abstract: A superabsorbent polymer dressing having antimicrobial properties for use in fabricating wound dressings, sanitary napkins, tampons and the like, includes a synthetic polymer matrix fabricated to have an enhanced surface area. Antimicrobial compounds are coupled to the surface of the polymer matrix by non-siloxane bonds.

Abstract translation: 具有用于制造伤口敷料，卫生巾，卫生棉条等的抗微生物性能的超吸收性聚合物敷料包括制造成具有增强的表面积的合成聚合物基质。 抗微生物化合物通过非硅氧烷键与聚合物基质的表面偶联。

公开(公告)号：WO0222773A3

公开(公告)日：2003-10-09

申请号：PCT/EP0110668

申请日：2001-09-14

Applicant: SHELL INT RESEARCH ,  CORCHO-SANCHEZ DIEGO ,  LERNER DAVID NICHOLAS ,  STEPHENSON RICHARD JOHN ,  WATKINSON ROBERT JAMES

Inventor： CORCHO-SANCHEZ DIEGO ,  LERNER DAVID NICHOLAS ,  STEPHENSON RICHARD JOHN ,  WATKINSON ROBERT JAMES

IPC: C02F3/10 ,  C12M1/12

CPC classification number: C12M29/04

Abstract: A bioreactor for microbial conversion of at least one conversion substrate, which comprises a treatment zone to accommodate when in use a solution of said at least one conversion substrate, a culture holding zone to accommodate when in use a microbial culture capable of metabolising said at least one conversion substrate, a source of primary growth substrate for the microbial culture, a first permeable membrane forming an interface between the treatment zone and the culture holding zone, and a second permeable membrane forming an interface between the source of primary growth substrate and the culture holding zone, the first permeable membrane being of a material which will allow passage of the at least one conversion substrate from the treatment zone to the culture holding zone whilst being impermeable to the microbial culture, the second permeable membrane being of a material permeable to the primary growth substrate but substantially impermeable to water; and a process of operating said bioreactor.

Abstract translation: 一种用于至少一种转化底物的微生物转化的生物反应器，其包含处理区，以在使用时适应所述至少一种转化底物的溶液，培养保持区，以在使用时适应能够代谢至少所述至少一种转化底物的微生物培养物 一个转化底物，用于微生物培养的一次生长底物源，形成处理区和培养保持区之间的界面的第一渗透膜，以及形成初级生长底物源和培养物之间的界面的第二渗透膜 所述第一渗透膜是允许所述至少一个转化基质从所述处理区通过所述培养保持区同时对所述微生物培养物不可渗透的材料，所述第二渗透膜是可透过的 初级生长基质，但基本上不透水; 以及操作所述生物反应器的过程。

公开(公告)号：WO1997002027A1

公开(公告)日：1997-01-23

申请号：PCT/US1996011318

申请日：1996-07-05

Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD. ,  GILAD, Gad ,  GILAD, Varda ,  STERLING, Jeffrey ,  HERZIG, Yaacov ,  LERNER, David ,  VEINBERG, Alex ,  MILMAN, Isaac ,  FINKELSTEIN, Nina

Inventor： TEVA PHARMACEUTICAL INDUSTRIES, LTD.

IPC: A61K31/15

CPC classification number: C07C279/12 ,  A61K31/135 ,  A61K31/155 ,  C07C211/42 ,  C07C233/41 ,  C07C2602/24

Abstract: A compound of general formula (I), wherein n is 1 or 2; R1 and R2 are each independently hydrogen, hydroxy, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy or halogeno; R5 is hydrogen, substituted or unsubstituted C1-4 alkyl, amino or NR6R7; R3, R4, R6 and R7 are each independently hydrogen or (CH2)m-[NH(CH2)x]y-NHR11 wherein m is from 0-5, y is from 0-5 and each x is independently from 1-5 and R11 is hydrogen or C(NH)NH2; provided that when R3 and R4 are both hydrogen, R5 is amino or NR6R7; pharmaceutically acceptable salts and optically active isomers thereof.

Abstract translation: 通式（I）的化合物，其中n为1或2; R 1和R 2各自独立地为氢，羟基，取代或未取代的C 1-4烷基，取代或未取代的C 1-4烷氧基或卤素; R5是氢，取代或未取代的C1-4烷基，氨基或NR6R7; R3，R4，R6和R7各自独立地为氢或（CH2）m- [NH（CH2）x] y-NHR11，其中m为0-5，y为0-5，并且各x独立地为1-5 和R 11是氢或C（NH）NH 2; 条件是当R3和R4都是氢时，R5是氨基或NR6R7; 其药学上可接受的盐和旋光异构体。

公开(公告)号：WO1995011016A1

公开(公告)日：1995-04-27

申请号：PCT/US1994011567

申请日：1994-10-12

Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. ,  YOUDIM, Moussa, B., H. ,  FINBERG, John, P., M. ,  LEVY, Ruth ,  STERLING, Jeffrey ,  LERNER, David ,  BERGER-PASKIN, Tirtsah ,  YELLIN, Haim ,  VEINBERG, Alex

Inventor： TEVA PHARMACEUTICAL INDUSTRIES LTD. ,  TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD.

IPC: A61K31/135

CPC classification number: C07C211/30 ,  A61K31/195 ,  A61K31/215 ,  A61K45/06 ,  C07C2602/08 ,  Y02A50/395 ,  A61K2300/00

Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.

Abstract translation: 本发明提供了R（+） - N-炔丙基-1-氨基茚满及其药学上可接受的盐，以及含有它们的药物组合物。 本发明还提供了治疗患有帕金森病，记忆障碍，痴呆，抑郁症，多动症综合征，情感疾病，神经变性疾病，神经毒性损伤，脑缺血，头部创伤损伤，脊髓损伤损伤 ，精神分裂症，注意力缺陷障碍，多发性硬化或戒断症状，​​使用本发明的R（+） - N-炔丙基-1-氨基茚满或其药学上可接受的盐。 本发明进一步提供一种预防受试者的神经损伤的方法。 最后，本发明提供了制备R（+） - N-炔丙基-1-氨基茚满其盐和外消旋的N-炔丙基-1-氨基茚满的方法。

公开(公告)号：WO1995001956A1

公开(公告)日：1995-01-19

申请号：PCT/US1994007498

申请日：1994-07-06

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  TEVA PHARMACEUTICAL INDUSTRIE, LTD. ,  BIALER, Meir ,  HADAD, Salim ,  HERZIG, Jacob ,  STERLING, Jeff ,  LERNER, David ,  SHIRVAN, Mitchell

Inventor： YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  TEVA PHARMACEUTICAL INDUSTRIE, LTD.

IPC: C07C237/12

CPC classification number: C07C233/49 ,  C07C233/47 ,  C07C237/22 ,  C07C255/29

Abstract: A compound having structure (I), wherein A is X or Y, X is (a), Y is (b); R1, R2, R3, R4 and R5 are each independently hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group; and n is 0, 1, 2, or 3. Also provided are a compound containing a 2-valproenoic moiety, pharmaceutical compositions comprising these compounds, and methods of using them for the effective treatment of epilepsy and other neurological disorders.

Abstract translation: 具有结构（I）的化合物，其中A是X或Y，X是（a），Y是（b）; R1，R2，R3，R4和R5各自独立地为氢，C1-C6烷基，芳烷基或芳基; 并且n为0,1,2或3.还提供含有2-戊烯基部分的化合物，包含这些化合物的药物组合物，及其用于有效治疗癫痫和其它神经障碍的方法。

公开(公告)号：WO03039602A2

公开(公告)日：2003-05-15

申请号：PCT/US0230998

申请日：2002-09-30

Applicant: QUICK MED TECHNOLOGIES INC ,  UNIV FLORIDA ,  BATICH CHRISTOPHER D ,  SCHULTZ GREGORY ,  MAST BRUCE A ,  OLDERMAN GERALD M ,  LERNER DAVID S ,  TOREKI WILLIAM ,  GRANITO MICHAEL R

Inventor： BATICH CHRISTOPHER D ,  SCHULTZ GREGORY ,  MAST BRUCE A ,  OLDERMAN GERALD M ,  LERNER DAVID S ,  TOREKI WILLIAM ,  GRANITO MICHAEL R

IPC: A61F13/15 ,  A61L15/46 ,  A61L

CPC classification number: A01N25/34 ,  A61F13/8405 ,  A61L15/46 ,  A61L2300/206 ,  A61L2300/208 ,  A61L2300/404 ,  A61L2300/606 ,  A01N25/10 ,  A01N33/12 ,  A01N47/44

Abstract: This invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings, powders and other substrates. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymer chains and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial efficacy.

Abstract translation: 本发明涉及具有抗菌性能的非浸出涂层的材料的方法和组合物。 将涂层施加到诸如纱布式伤口敷料，粉末和其它底物的基底上。 在底物和形成涂层的聚合物分子之间形成共价，非浸出，不可水解的键。 在多长度聚合物链上具有高浓度的抗微生物群和相当长的平均链长，有助于具有高水平抗微生物效能的吸收剂或超吸收剂表面。